Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Abstract

This study provides Class I evidence (based on rater blinding and a balance in baseline characteristics between arms) that alemtuzumab modifies disability measures favorably compared with SC IFN-β-1a.